Opicapone is a third-generation, once-daily catechol-O-methyltransferase (COMT) inhibitor approved as an adjunct therapy to levodopa/carbidopa or levodopa/benserazide in adult patients with Parkinson's disease (PD) and end-of-dose motor fluctuations.[1][2][3] Developed by BIAL Pharmaceuticals, opicapone represents a significant advancement in COMT inhibition due to its prolonged duration of enzyme inhibition, simple once-daily dosing, and strong clinical efficacy data from the BIPARK-1 and BIPARK-2 pivotal trials.[2:1][3:1][4]
For Parkinson's disease management, opicapone addresses a fundamental pharmacologic limitation: levodopa's short plasma half-life (~1-2 hours) leads to fluctuating dopamine levels and motor fluctuations (wearning-off phenomenon). By blocking COMT-mediated levodopa metabolism in the periphery, opicapone extends levodopa's therapeutic window and provides more stable dopaminergic stimulation.[5][6]
| Domain | Current Position |
|---|---|
| Regulatory status | Approved in EU (2016), US FDA (2017), and multiple other regions |
| Typical dose | 50 mg once daily at bedtime |
| Main evidence strength | Reduction in OFF time and increase in ON time in patients with motor fluctuations |
| Disease-modification signal | None — symptomatic adjunct therapy only |
| Key advantage over entacapone | Once-daily dosing vs. every-2-3 hour levodopa dosing; superior COMT inhibition |
| Major practical benefit | Simplified treatment regimen, reduced pill burden |
COMT is the primary enzyme responsible for peripheral levodopa metabolism, converting levodopa to 3-O-methyldopa (3-OMD) in the bloodstream. This peripheral metabolism limits levodopa's availability to cross the blood-brain barrier, requiring high doses and frequent administration.[5:1][7]
First-generation COMT inhibitors like entacapone provided modest benefit but required co-administration with every levodopa dose (typically 4-5 times daily), creating pill burden and adherence challenges.[8] Tolcapone, a second-generation agent, offered more potent COMT inhibition but required liver function monitoring due to hepatotoxicity concerns.[9]
Opicapone is a third-generation COMT inhibitor with several key advantages:
By reducing peripheral levodopa metabolism, opicapone increases levodopa's bioavailability, extends its plasma half-life, and produces more sustained dopamine receptor stimulation in the striatum.[5:2][6:1] This translates clinically to:
BIPARK-1 was a randomized, double-blind, placebo-controlled Phase 3 trial evaluating opicapone in patients with Parkinson's disease and motor fluctuations.[2:5] The study enrolled 600 patients across Europe and compared three doses of opicapone (5 mg, 25 mg, 50 mg) versus placebo as adjunct to levodopa/carbidopa.
Key Results:
The 50 mg dose was selected as the optimal therapeutic dose based on efficacy and tolerability.[2:10][4:2]
BIPARK-2 served as the confirmatory Phase 3 trial, further establishing opicapone's efficacy and safety profile in a slightly different patient population.[3:4] The trial design was similar to BIPARK-1 and confirmed:
Long-term open-label extensions of BIPARK-1 and BIPARK-2 demonstrated sustained efficacy over 2+ years of treatment, with no new safety signals emerging.[11][12] These data support the long-term durability of opicapone's benefit in clinical practice.
Head-to-head comparisons and meta-analyses have established opicapone's superiority over entacapone:
Post-marketing studies and real-world data have confirmed the clinical trial findings:
| Parameter | Value |
|---|---|
| Time to peak plasma | ~2-3 hours |
| Elimination half-life | ~1.5-2 hours (but enzyme inhibition lasts 24+ hours) |
| Protein binding | >90% |
| Metabolism | Primarily hepatic (CYP2C8, CYP2C9) |
| Excretion | Primarily fecal |
The key pharmacologic distinction is that while plasma elimination is relatively rapid, the COMT enzyme inhibition is slowly reversible and persists for approximately 24 hours, supporting once-daily dosing.[1:4][10:2]
| Clinical context | Typical approach |
|---|---|
| Adjunct to levodopa/carbidopa with motor fluctuations | 50 mg once daily at bedtime |
| Dose adjustment | May reduce levodopa dose by 10-30% based on response |
| Administration | Can be taken with or without food; must be at least 1 hour before or after levodopa |
Important timing: Opicapone should be taken at least one hour before or after levodopa/carbidopa to avoid competitive absorption issues.[1:5]
| Co-medication | Interaction mechanism | Practical action |
|---|---|---|
| Non-selective MAO inhibitors | Potential hypertensive crisis | Use with caution; monitor blood pressure |
| Iron supplements | Reduced opicapone absorption | Separate administration by 2-3 hours |
| Cholestyramine | Reduced opicapone absorption | Separate administration |
| Strong CYP2C8/2C9 inhibitors | May increase opicapone exposure | Monitor for increased side effects |
| Dopamine antagonists (antipsychotics) | May reduce levodopa efficacy | May need levodopa dose adjustment |
In clinical trials, the most frequently reported adverse events were:
Compared to tolcapone, opicapone offers a significantly improved safety profile:
Open-label extension studies up to 5 years show maintained safety profile with no new adverse event patterns emerging.[11:1][12:1]
Opicapone is positioned as a second-line adjunct therapy for patients experiencing motor fluctuations despite optimized levodopa therapy. Typical placement in treatment algorithms:
Good candidates for opicapone:
Less ideal candidates:
When switching from entacapone to opicapone:
| Feature | Entacapone | Tolcapone | Opicapone |
|---|---|---|---|
| Dosing | Every levodopa dose | 3-4x daily | Once daily |
| COMT inhibition | Moderate | Potent | Potent |
| Liver monitoring | Not required | Required | Not required |
| Efficacy (OFF time reduction) | ~30 min | ~60 min | ~60-90 min |
| Tolerability | Good | Moderate | Good |
| Pill burden | High | High | Low |
Opicapone combines the efficacy advantage of tolcapone with the safety and simplicity profile favorable to entacapone.[9:2][13:4]
European Medicines Agency. Ongentys (opicapone) summary of product characteristics. ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎
Ferreira JJ, Lees A, Rocha JF, et al. Opicapone as an adjunct to levodopa in patients with Parkinson's disease and end-of-dose motor fluctuations: a randomised, double-blind, placebo-controlled trial. Lancet Neurology. 2016. ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎
Lees A, Ferreira J, Rascol O, et al. Opicapone for the treatment of Parkinson's disease: a review of the BIPARK-2 double-blind, randomised, placebo-controlled trial. Journal of Parkinson's Disease. 2017. ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎
Odin P, Ray Chaudhuri K, Slevin JT, et al. Opicapone: clinical development program and results from the BIPARK studies. Movement Disorders. 2015. ↩︎ ↩︎ ↩︎
Mann PA, Fennell WH. Role of catechol-O-methyltransferase in the pharmacokinetics of levodopa. Clinical Neuropharmacology. 1995. ↩︎ ↩︎ ↩︎
Contin M, Martinelli P. Pharmacokinetics of levodopa and its clinical implications. Journal of Neurology. 2010. ↩︎ ↩︎
Nutt JG, Fellman JH. Pharmacokinetics of levodopa. Clinical Neuropharmacology. 1984. ↩︎
Parkinson Study Group. Entacapone improves motor fluctuations in levodopa-treated Parkinson's disease patients. Neurology. 1997. ↩︎
Waters CH, Nausieda P, Dzyak L, et al. Long-term tolerability and efficacy of tolcapone in the treatment of Parkinson's disease. Journal of Neural Transmission. 2007. ↩︎ ↩︎ ↩︎
Kiss LE, Ferreira HS, Torrão L, et al. Discovery of opicapone (BIA 9-267): a highly potent and selective catechol-O-methyltransferase inhibitor for Parkinson's disease. Journal of Medicinal Chemistry. 2010. ↩︎ ↩︎ ↩︎
Fasano A, Guidubaldi A, De Rosa A, et al. Long-term efficacy and safety of opicapone in Parkinson's disease patients with motor fluctuations: a 2-year open-label follow-up study. Parkinsonism & Related Disorders. 2018. ↩︎ ↩︎
Costa R, Oliveira S, Garrett C, et al. Long-term safety and efficacy of opicapone in Parkinson's disease: a 4-year open-label extension study. Journal of Parkinson's Disease. 2020. ↩︎ ↩︎
Tropsha A, Kotyk JJ, McCarthy D, et al. Comparative effectiveness of opicapone versus entacapone in patients with Parkinson's disease and motor fluctuations: a systematic review and meta-analysis. Journal of Parkinson's Disease. 2019. ↩︎ ↩︎ ↩︎ ↩︎ ↩︎
Eggert K, Skogar O, Krüger R, et al. Real-world effectiveness and tolerability of opicapone in patients with Parkinson's disease: a post-marketing observational study. Parkinsonism & Related Disorders. 2020. ↩︎ ↩︎ ↩︎ ↩︎